The cost reduction was large. It limits the cost opportunity in...

First 5 Last

Share
Profile

Follow
tdubs

197 Posts.

77

29/08/18

10:14

Post #: 35256548
Share

Originally posted by SimonGr ↑

I'm still digesting, however ...

- $12M 'loss' that you quote is made up of significant non-cash accounting changes that make this year worse ... but future years better, ie.
- extra $4.2M amortisation (one-off to reduce amortisation over 5 years vs previous 7)
- as RDF has tax losses on its balance sheet and Trump has reduced US Corp tax, there is a reduction in the carrying value of these ($3.0M)
- Therefore ... loss is really $4.9M.... driven by heavy investment in the Int Business (as per their business plan at capital raising).

This is a technology business that is investing to grow again. With a market cap of $54M today, this entire business is being priced at just 5 x FY18 EBITDA of its "Americas" division which is sticky annuity type revenue (and assigning zero value to the International business that they're spending all the cash investing in!).

So ... if you have no faith that they'll achieve their goals in the Int Business you should stay away. However, I'm betting that they will be successful in winning contracts over the next 12-36 months and we'll see a significant re-rating of the shares, starting with their first major contract win.... or maybe even earlier with this result!

Expand

The cost reduction was large. It limits the cost opportunity in the future, however it also magnifies operating leverage. If they win a couple of big contracts (and it's an if) the pay-off will be very strong.

Last edited by tdubs: 29/08/18

RDF Price at posting: 34.5¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

'Not possible' to port renewable gas: ACCC takes AGN to court

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

First 5 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

The cost reduction was large. It limits the cost opportunity in...

Top Stories

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Boss extends June win streak with boosted Alta Mesa extraction rates

'Not possible' to port renewable gas: ACCC takes AGN to court

Australia’s gas crisis is here – and dying coal plants aren’t helping

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News